ABEO
Abeona Therapeutics Inc
5.40$
-0.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 69.7% | 50.7% | 62.5% | 78.6% | 50.9% | 59.3% | 64.6% | 70.7% | 82.7% | 87.1% | 92.6% | 93.3% | |
| 69.5% | 50.1% | 62.3% | 77.1% | 10.8% | 57.9% | 8.3% | 41.4% | 22.1% | 22.6% | 21.4% | 35.7% | |
| 69.5% | 50.1% | 62.3% | 77.1% | 48.7% | 57.9% | 62.9% | 56.6% | 81.2% | 81.6% | 89.7% | 87.2% | |
| 0.2% | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 3.8% | 0.3% | 3.8% | 1.5% | 3.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | 0.0% | 0.5% | – | 0.0% | 2.5% | |
| 0.0% | 0.4% | 0.6% | 0.8% | 5.4% | 5.9% | 12.1% | 27.3% | 17.2% | – | – | – | |
| 0.0% | 40.6% | 29.2% | 18.2% | 18.6% | 14.5% | 21.5% | 0.0% | – | – | – | – | |
| 30.1% | 8.3% | 7.5% | 2.2% | 24.7% | 16.2% | 1.0% | 1.7% | – | – | – | – | |
| 71.0% | 15.4% | 10.8% | 4.8% | 23.1% | 20.1% | 32.2% | 46.8% | 58.3% | 76.8% | 59.6% | 27.5% | |
| 17.5% | 1.8% | 7.5% | 3.1% | 11.7% | 17.3% | 27.8% | 20.9% | 12.1% | 21.0% | 15.2% | 13.5% | |
| 2.4% | -0.8% | – | -2.1% | 5.7% | 0.8% | 1.4% | 2.3% | 2.8% | 1.6% | 6.2% | 6.0% | |
| 11.4% | 1.1% | 3.3% | 1.1% | 3.5% | 1.7% | 3.1% | 5.4% | 2.8% | 2.9% | 3.2% | 3.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 11.5% | – | 0.9% | – | – | – | 12.0% | 3.6% | |
| 29.0% | 84.6% | 89.2% | 95.2% | 76.9% | 79.9% | 67.8% | 53.2% | 41.7% | 23.2% | 40.4% | 72.5% | |
| -1,785.5% | -388.0% | -299.4% | -201.3% | -235.2% | -217.8% | -377.5% | -823.8% | -1,082.8% | -1,171.1% | -746.6% | -338.0% | |
| 0.1% | 1.4% | 1.2% | 0.9% | 1.1% | 0.9% | 2.5% | 4.9% | 12.2% | 33.4% | 37.7% | 30.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.